Cellosaurus logo
expasy logo

Cellosaurus A375-VR [2014] (CVCL_AP96)

[Text version]
Cell line name A375-VR [2014]
Accession CVCL_AP96
Resource Identification Initiative To cite this cell line use: A375-VR [2014] (RRID:CVCL_AP96)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
Derived from site: In situ; Skin; UBERON=UBERON_0002097.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0132 (A-375)
Sex of cell Female
Age at sampling 54Y
Category Cancer cell line

PubMed=24398428; DOI=10.1158/1535-7163.MCT-13-0481
Acquaviva J., Smith D.L., Jimenez J.-P., Zhang C.-H., Sequeira M., He S.-Q., Sang J., Bates R.C., Proia D.A.
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Mol. Cancer Ther. 13:353-363(2014)

Cell line databases/resources cancercelllines; CVCL_AP96
Encyclopedic resources Wikidata; Q54606865
Entry history
Entry creation02-May-2016
Last entry update05-Oct-2023
Version number14